{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-000156","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.456084+00:00","generated_at":"2026-06-27T19:12:02.722386+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RxSight Q4 revenue ~$8.4M (+71% YoY); full year 2021 revenue ~$22.6M (+54% YoY)","bullets":["Q4 2021 revenue ~$8.4M, up 71% YoY; sold 45 LDDs (installed base 206) and 2,959 LALs.","FY 2021 revenue ~$22.6M, up 54% YoY; 114 LDDs and 8,328 LALs sold.","Cash, equivalents and short-term investments ~$159.3M as of Dec 31, 2021.","CEO Ron Kurtz cites continued adoption and ActivShield rollout as growth drivers for 2022.","Results are preliminary; audited Q4 and FY 2021 results expected in early March."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-000156","json":"https://secwatch.observer/filing/0000950170-22-000156.json","markdown":"https://secwatch.observer/filing/0000950170-22-000156.md","text":"https://secwatch.observer/filing/0000950170-22-000156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022000156/0000950170-22-000156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022000156/rxst-20220109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:12:02.722386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}